Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: Its role in modulating protein function

Frontiers in Oncology

Volumn 4 MAR, Issue , 2014, Pages

  Sharom, Frances Jane ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

ATP hydrolysis; Cholesterol; Detergents; Drug binding; Membrane partitioning; Membrane transport; P glycoprotein (ABCB1); Phospholipids

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARRIER PROTEIN; DETERGENT; EDELFOSINE; GLYCOSPHINGOLIPID; MEMBRANE LIPID; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; PROTEOLIPOSOME; SPHINGOMYELIN;

BILAYER MEMBRANE; CRYSTAL STRUCTURE; ELECTRON MICROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; MASS SPECTROMETRY; MEMBRANE POTENTIAL; MEMBRANE VESICLE; NUCLEAR MAGNETIC RESONANCE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN LIPID INTERACTION; REVIEW;

EID: 84901070245     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00041     Document Type: Review

References (180)

1. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 5:219-34. doi: 10.1038/nrd1984.
2. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol (1999) 39:361-98. doi:10.1146/annurev.pharmtox.39.1.361.
3. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics (2008) 9:105-27. doi:10.2217/14622416.9.1.105.
4. Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev (2009) 109:2989-3011. doi:10.1021/cr9000226.
5. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta (1976) 455:152-62. doi:10.1016/0005-2736(76)90160-7.
6. Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol (1997) 160:161-75. doi:10.1007/s002329900305.
7. Ferté J. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem (2000) 267:277-94. doi:10.1046/j.1432-1327.2000.01046.x.
8. Sharom FJ. The P-glycoprotein multidrug transporter: interactions with membrane lipids, and their modulation of activity. Biochem Soc Trans (1997) 25:1088-96.
9. Callaghan R, Stafford A, Epand RM. Increased accumulation of drugs in a multidrug resistant cell line by alteration of membrane biophysical properties. Biochim Biophys Acta (1993) 1175:277-82. doi:10.1016/0167-4889(93)90217-D.
10. Kodan A, Shibata H, Matsumoto T, Terakado K, Sakiyama K, Matsuo M, et al. Improved expression and purification of human multidrug resistance protein MDR1 from baculovirus-infected insect cells. Protein Expr Purif (2009) 66:7-14. doi:10.1016/j.pep.2009.02.010.
11. Melchior DL, Sharom FJ, Evers R, Wright GE, Chu JW, Wright SE, et al. Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers. J Pharmacol Toxicol Methods (2012) 65:64-74. doi:10.1016/j.vascn.2012.02.002.
12. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest (1995) 95:2205-14. doi:10.1172/JCI117910.
13. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 87:7160-4. doi:10.1073/pnas.87.18.7160.
14. Lum BL, Gosland MP, Kaubisch S, Sikic BI. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy (1993) 13:88-109.
15. Mattern J. Drug resistance in cancer: a multifactorial problem. Anticancer Res (2003) 23:1769-72.
16. Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE. The controversial role of ABC transporters in clinical oncology. Essays Biochem (2011) 50:209-32. doi:10.1042/bse0500209.
17. Chan HS, DeBoer G, Thiessen JJ, Budning A, Kingston JE, O'Brien JM, et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res (1996) 2:1499-508.
18. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist (2003) 8:411-24. doi:10.1634/theoncologist.8-5-411.
19. Robey RW, Massey PR, Amiri-Kordestani L, Bates SE. ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem (2010) 10:625-33. doi:10.2174/187152010794473957.
20. Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem (2007) 296:85-95. doi:10.1007/s11010-006-9302-8.
21. Michalak K, Wesolowska O. Polyphenols counteract tumor cell chemoresistance conferred by multidrug resistance proteins. Anticancer Agents Med Chem (2012) 12:880-90. doi:10.2174/187152012802650011.
22. Di Pietro A, Conseil G, Perez-Victoria JM, Dayan G, Baubichon-Cortay H, Trompier D, et al. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci (2002) 59:307-22. doi:10.1007/s00018-002-8424-8.
23. Siarheyeva A, Lopez JJ, Glaubitz C. Localization of multidrug transporter substrates within model membranes. Biochemistry (2006) 45:6203-11. doi:10.1021/bi0524870.
24. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem (1993) 268:21493-6.
25. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem (1990) 265:3975-80.
26. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? Trends Biochem Sci (1992) 17:18-21. doi:10.1016/0968-0004(92)90419-A.
27. Shapiro AB, Corder AB, Ling V. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem (1997) 250:115-21. doi:10.1111/j.1432-1033.1997.00115.x.
28. Loo TW, Clarke DM. The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J Biol Chem (1999) 274:24759-65. doi:10.1074/jbc.274.35.24759.
29. Shapiro AB, Ling V. Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein. Eur J Biochem (1997) 250:122-9. doi:10.1111/j.1432-1033.1997.00122.x.
30. Shapiro AB, Ling V. Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein. Eur J Biochem (1998) 254:181-8. doi:10.1046/j.1432-1327.1998.2540181.x.
31. Katzir H, Yeheskely-Hayon D, Regev R, Eytan GD. Role of the plasma membrane leaflets in drug uptake and multidrug resistance. FEBS J (2010) 277:1234-44. doi:10.1111/j.1742-4658.2009.07555.x.
32. Qu Q, Sharom FJ. Proximity of bound Hoechst 33342 to the ATPase catalytic sites places the drug binding site of P-glycoprotein within the cytoplasmic membrane leaflet. Biochemistry (2002) 41:4744-52. doi:10.1021/bi0120897.
33. Lugo MR, Sharom FJ. Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry (2005) 44:643-55. doi:10.1021/bi0511179.
34. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science (2009) 323:1718-22. doi:10.1126/science.1168750.
35. Jin MS, Oldham ML, Zhang Q, Chen J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature (2012) 490:566-9. doi:10.1038/nature11448.
36. Eytan GD. Mechanism of multidrug resistance in relation to passive membrane permeation. Biomed Pharmacother (2005) 59:90-7. doi:10.1016/j.biopha.2005.01.003.
37. Eytan GD, Regev R, Oren G, Assaraf YG. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem (1996) 271:12897-902. doi:10.1074/jbc.271.22.12897.
38. Abulrob AG, Gumbleton M. Transport of phosphatidylcholine in MDR3-negative epithelial cell lines via drug-induced MDR1 P-glycoprotein. Biochem Biophys Res Commun (1999) 262:121-6. doi:10.1006/bbrc.1999.1120.
39. Bosch I, Dunussi-Joannopoulos K, Wu RL, Furlong ST, Croop J. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry (1997) 36:5685-94. doi:10.1021/bi962728r.
40. van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell (1996) 87:507-17. doi:10.1016/S0092-8674(00)81370-7.
41. van Helvoort A, Giudici ML, Thielemans M, van Meer G. Transport of sphingomyelin to the cell surface is inhibited by brefeldin A and in mitosis, where C6-NBD-sphingomyelin is translocated across the plasma membrane by a multidrug transporter activity. J Cell Sci (1997) 110:75-83.
42. Pohl A, Lage H, Muller P, Pomorski T, Herrmann A. Transport of phosphatidylserine via MDR1 (multidrug resistance 1) P-glycoprotein in a human gastric carcinoma cell line. Biochem J (2002) 365:259-68. doi:10.1042/BJ20011880.
43. Romsicki Y, Sharom FJ. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry (2001) 40:6937-47. doi:10.1021/bi0024456.
44. Eckford PD, Sharom FJ. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem J (2005) 389:517-26. doi:10.1042/BJ20050047.
45. Eckford PD, Sharom FJ. P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors. Biochem Cell Biol (2006) 84:1022-33. doi:10.1139/o06-196.
46. Raggers RJ, Vogels I, van Meer G. Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. Biochem J (2001) 357:859-65. doi:10.1042/0264-6021:3570859.
47. Ernest S, Bello-Reuss E. Secretion of platelet-activating factor is mediated by MDR1 P-glycoprotein in cultured human mesangial cells. J Am Soc Nephrol (1999) 10:2306-13.
48. Rybczynska M, Liu R, Lu P, Sharom FJ, Steinfels E, Pietro AD, et al. MDR1 causes resistance to the antitumour drug miltefosine. Br J Cancer (2001) 84:1405-11. doi:10.1054/bjoc.2001.1776.
49. Ruetz S, Brault M, Dalton W, Gros P. Functional interactions between synthetic alkyl phospholipids and the ABC transporters P-glycoprotein, Ste-6, MRP, and Pgh 1. Biochemistry (1997) 36:8180-8.
50. Sharom FJ, Yu X, Chu JW, Doige CA. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochem J (1995) 308:381-90.
51. Marcoux J, Wang SC, Politis A, Reading E, Ma J, Biggin PC, et al. Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump. Proc Natl Acad Sci U S A (2013) 110:9704-9. doi:10.1073/pnas.1303888110.
52. Bello-Reuss E, Ernest S, Holland OB, Hellmich MR. Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am J Physiol Cell Physiol (2000) 278:C1256-65.
53. Liu Y, Huang L, Hoffman T, Gosland M, Vore M. MDR1 substrates/modulators protect against β-estradiol-17β-D-glucuronide cholestasis in rat liver. Cancer Res (1996) 56:4992-7.
54. Orlowski S, Mir LM, Belehradek J Jr, Garrigos M. Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J (1996) 317(Pt 2):515-22.
55. Rao US, Fine RL, Scarborough GA. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol (1994) 48:287-92. doi:10.1016/0006-2952(94)90099-X.
56. Ruetz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell (1994) 77:1071-81. doi:10.1016/0092-8674(94)90446-4.
57. Smith AJ, Timmermans-Hereijgers JL, Roelofsen B, Wirtz KW, van Blitterswijk WJ, Smit JJ, et al. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett (1994) 354:263-6. doi:10.1016/0014-5793(94)01135-4.
58. Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, et al. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem (2000) 275:23530-9. doi:10.1074/jbc.M909002199.
59. Frijters CMG, Tuijn CJ, Ottenhoff R, Zegers BN, Groen AK, Elferink RPJO. The role of different P-glycoproteins in hepatobiliary secretion of fluorescently labeled short-chain phospholipids. J Lipid Res (1999) 40:1950-7.
60. Sharom FJ. Flipping and flopping-lipids on the move. IUBMB Life (2011) 63:736-46. doi:10.1002/iub.515.
61. Quazi F, Molday RS. Lipid transport by mammalian ABC proteins. Essays Biochem (2011) 50:265-90. doi:10.1042/bse0500265.
62. Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim Biophys Acta (2000) 1486:128-44. doi:10.1016/S1388-1981(00)00053-6.
63. van Meer G, Halter D, Sprong H, Somerharju P, Egmond MR. ABC lipid transporters: extruders, flippases, or flopless activators? FEBS Lett (2006) 580:1171-7. doi:10.1016/j.febslet.2005.12.019.
64. Quazi F, Molday RS. Differential phospholipid substrates and directional transport by ATP binding cassette proteins ABCA1, ABCA7, and ABCA4 and disease-causing mutants. J Biol Chem (2013) 288:34414-26. doi:10.1074/jbc.M113.508812.
65. Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem (2011) 50:161-78. doi:10.1042/bse0500161.
66. Zolnerciks JK, Andress EJ, Nicolaou M, Linton KJ. Structure of ABC transporters. Essays Biochem (2011) 50:43-61. doi:10.1042/bse0500043.
67. Holland IB, Blight MA. ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. J Mol Biol (1999) 293:381-99. doi:10.1006/jmbi.1999.2993.
68. Jones PM, George AM. Subunit interactions in ABC transporters: towards a functional architecture. FEMS Microbiol Lett (1999) 179:187-202. doi:10.1111/j.1574-6968.1999.tb08727.x.
69. Jones PM, George AM. Mechanism of the ABC transporter ATPase domains: catalytic models and the biochemical and biophysical record. Crit Rev Biochem Mol Biol (2013) 48:39-50. doi:10.3109/10409238.2012.735644.
70. George AM, Jones PM. Perspectives on the structure-function of ABC transporters: the Switch and Constant Contact models. Prog Biophys Mol Biol (2012) 109:95-107. doi:10.1016/j.pbiomolbio.2012.06.003.
71. Sharom FJ, Liu R, Romsicki Y. Spectroscopic and biophysical approaches for studying the structure and function of the P-glycoprotein multidrug transporter. Biochem Cell Biol (1998) 76:695-708. doi:10.1139/o98-075.
72. Rosenberg MF, Callaghan R, Modok S, Higgins CF, Ford RC. Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J Biol Chem (2005) 280:2857-62. doi:10.1074/jbc.M410296200.
73. Lee JY, Urbatsch IL, Senior AE, Wilkens S. Projection structure of P-glycoprotein by electron microscopy. Evidence for a closed conformation of the nucleotide binding domains. J Biol Chem (2002) 277:40125-31. doi:10.1074/jbc.M206871200.
74. Lee JY, Urbatsch IL, Senior AE, Wilkens S. Nucleotide-induced structural changes in P-glycoprotein observed by electron microscopy. J Biol Chem (2008) 283:5769-79. doi:10.1074/jbc.M707028200.
75. Lugo MR, Sharom FJ. Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs. Biochemistry (2005) 44:14020-9. doi:10.1021/bi0511179.
76. Lugo MR, Sharom FJ. Interaction of LDS-751 with the drug-binding site of P-glycoprotein: a Trp fluorescence steady-state and lifetime study. Arch Biochem Biophys (2009) 492:17-28. doi:10.1016/j.abb.2009.10.002.
77. Loo TW, Clarke DM. Mutational analysis of ABC proteins. Arch Biochem Biophys (2008) 476:51-64. doi:10.1016/j.abb.2008.02.025.
78. Pleban K, Kopp S, Csaszar E, Peer M, Hrebicek T, Rizzi A, et al. P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach. Mol Pharmacol (2005) 67:365-74. doi:10.1124/mol.104.006973.
79. Parveen Z, Stockner T, Bentele C, Pferschy S, Kraupp M, Freissmuth M, et al. Molecular dissection of dual pseudosymmetric solute translocation pathways in human P-glycoprotein. Mol Pharmacol (2011) 79:443-52. doi:10.1124/mol.110.067611.
80. Ward AB, Szewczyk P, Grimard V, Lee CW, Martinez L, Doshi R, et al. Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc Natl Acad Sci U S A (2013) 110:13386-91. doi:10.1073/pnas.1309275110.
81. Loo TW, Clarke DM. Drug rescue distinguishes between different structural models of human P-glycoprotein. Biochemistry (2013) 52:7167-9. doi:10.1021/bi401269m.
82. Wen PC, Verhalen B, Wilkens S, Mchaourab HS, Tajkhorshid E. On the origin of large flexibility of P-glycoprotein in the inward-facing state. J Biol Chem (2013) 288:19211-20. doi:10.1074/jbc.M113.450114.
83. al-Shawi MK, Senior AE. Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein. J Biol Chem (1993) 268:4197-206.
84. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem (1992) 267:24995-5002.
85. Sharom FJ, Eckford PD. Reconstitution of membrane transporters. Methods Mol Biol (2003) 227:129-54.
86. Urbatsch IL, Senior AE. Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein. Arch Biochem Biophys (1995) 316:135-40. doi:10.1006/abbi.1995.1020.
87. Sharom FJ, Yu X, Doige CA. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem (1993) 268:24197-202.
88. Shapiro AB, Ling V. Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem (1995) 270:16167-75. doi:10.1074/jbc.270.27.16167.
89. Ambudkar SV. Purification and reconstitution of functional human P-glycoprotein. J Bioenerg Biomembr (1995) 27:23-9. doi:10.1007/BF02110327.
90. Sharom FJ. Multidrug resistance protein: P-glycoprotein. In: You G, Morris ME, editors. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Hoboken, NJ: John Wiley & Sons (2007). p. 223-62.
91. Ritchie TK, Kwon H, Atkins WM. Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2. J Biol Chem (2011) 286:39489-96. doi:10.1074/jbc.M111.284554.
92. Dong M, Penin F, Baggetto LG. Efficient purification and reconstitution of P-glycoprotein for functional and structural studies. J Biol Chem (1996) 271:28875-83. doi:10.1074/jbc.271.46.28875.
93. Sharom FJ, Liu R, Vinepal B. Fluorescence studies of drug binding and translocation by membrane transporters. In: Yan Q, editor. Methods in Molecular Biology: Membrane Transporters in Drug Discovery and Development. Totowa, NJ: Springer Science+Business Media (2009). p. 133-48.
94. Sharom FJ. Characterization and functional reconstitution of the multidrug transporter. J Bioenerg Biomembr (1995) 27:15-22. doi:10.1007/BF02110326.
95. Doige CA, Yu X, Sharom FJ. ATPase activity of partially purified P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochim Biophys Acta (1992) 1109:149-60. doi:10.1016/0005-2736(92)90079-2.
96. Doige CA, Yu X, Sharom FJ. The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochim Biophys Acta (1993) 1146:65-72. doi:10.1016/0005-2736(93)90339-2.
97. Orlowski S, Selosse MA, Boudon C, Micoud C, Mir LM, Belehradek J Jr, et al. Effects of detergents on P-glycoprotein ATPase activity: differences in perturbations of basal and verapamil-dependent activities. Cancer Biochem Biophys (1998) 16:85-110.
98. Callaghan R, Berridge G, Ferry DR, Higgins CF. The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface. Biochim Biophys Acta (1997) 1328:109-24. doi:10.1016/S0005-2736(97)00079-5.
99. Beck A, Aanismaa P, Li-Blatter X, Dawson R, Locher K, Seelig A. Sav1866 from Staphylococcus aureus and P-glycoprotein: similarities and differences in ATPase activity assessed with detergents as allocrites. Biochemistry (2013) 52:3297-309. doi:10.1021/bi400203d.
100. Naito M, Tsuruo T. Reconstitution of purified P-glycoprotein into liposomes. J Cancer Res Clin Oncol (1995) 121:582-6. doi:10.1007/BF01197774.
101. Naito M, Tsuruo T. Functionally active homodimer of P-glycoprotein in multidrug-resistant tumor cells. Biochem Biophys Res Commun (1992) 185:284-90. doi:10.1016/S0006-291X(05)80988-X.
102. Boscoboinik D, Debanne MT, Stafford AR, Jung CY, Gupta RS, Epand RM. Dimerization of the P-glycoprotein in membranes. Biochim Biophys Acta (1990) 1027:225-8. doi:10.1016/0005-2736(90)90311-B.
103. Sehested M, Simpson D, Skovsgaard T, Buhl-Jensen P. Freeze-fracture study of plasma membranes in wild type and daunorubicin-resistant Ehrlich ascites tumor and P388 leukemia cells. Virchows Arch B Cell Pathol Incl Mol Pathol (1989) 56:327-35. doi:10.1007/BF02890034.
104. Loo TW, Clarke DM. The minimum functional unit of human P-glycoprotein appears to be a monomer. J Biol Chem (1996) 271:27488-92. doi:10.1074/jbc.271.44.27488.
105. Poruchynsky MS, Ling V. Detection of oligomeric and monomeric forms of P-glycoprotein in multidrug resistant cells. Biochemistry (1994) 33:4163-74. doi:10.1021/bi00196a023.
106. Taylor JC, Horvath AR, Higgins CF, Begley GS. The multidrug resistance P-glycoprotein. Oligomeric state and intramolecular interactions. J Biol Chem (2001) 276:36075-8. doi:10.1074/jbc.C100345200.
107. Loe DW, Sharom FJ. Interaction of multidrug-resistant Chinese hamster ovary cells with amphiphiles. Br J Cancer (1993) 68:342-51. doi:10.1038/bjc.1993.338.
108. Zordan-Nudo T, Ling V, Liu Z, Georges E. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res (1993) 53:5994-6000.
109. Sharom FJ, Liu R, Romsicki Y, Lu P. Insights into the structure and substrate interactions of the P-glycoprotein multidrug transporter from spectroscopic studies. Biochim Biophys Acta (1999) 1461:327-45. doi:10.1016/S0005-2736(99)00166-2.
110. Charuk JH, Grey AA, Reithmeier RA. Identification of the synthetic surfactant nonylphenol ethoxylate: a P-glycoprotein substrate in human urine. Am J Physiol (1998) 274:F1127-39.
111. Li-Blatter X, Nervi P, Seelig A. Detergents as intrinsic P-glycoprotein substrates and inhibitors. Biochim Biophys Acta (2009) 1788:2335-44. doi:10.1016/j.bbamem.2009.07.010.
112. Li-Blatter X, Seelig A. Exploring the P-glycoprotein binding cavity with polyoxyethylene alkyl ethers. Biophys J (2010) 99:3589-98. doi:10.1016/j.bpj.2010.10.033.
113. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem (1998) 251:252-61. doi:10.1046/j.1432-1327.1998.2510252.x.
114. Li-Blatter X, Beck A, Seelig A. P-Glycoprotein-ATPase modulation: the molecular mechanisms. Biophys J (2012) 102:1383-93. doi:10.1016/j.bpj.2012.02.018.
115. Rothnie A, Theron D, Soceneantu L, Martin C, Traikia M, Berridge G, et al. The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence. Eur Biophys J (2001) 30:430-42. doi:10.1007/s002490100156.
116. Romsicki Y, Sharom FJ. Interaction of P-glycoprotein with defined phospholipid bilayers: a differential scanning calorimetric study. Biochemistry (1997) 36:9807-15. doi:10.1021/bi963120l.
117. Oleinikov VA, Fleury F, Ianoul A, Zaitsev S, Nabiev I. P-glycoprotein effect on the properties of its natural lipid environment probed by Raman spectroscopy and Langmuir-Blodgett technique. FEBS Lett (2006) 580:4953-8. doi:10.1016/j.febslet.2006.07.069.
118. Lentz BR, Clubb KW, Barrow DA, Meissner G. Ordered and disordered phospholipid domains coexist in membranes containing the calcium pump protein of sarcoplasmic reticulum. Proc Natl Acad Sci U S A (1983) 80:2917-21. doi:10.1073/pnas.80.10.2917.
119. Chicken CA, Sharom FJ. Lipid-protein interactions of the human erythrocyte concanavalin A receptor in phospholipid bilayers. Biochim Biophys Acta (1984) 774:110-8. doi:10.1016/0005-2736(84)90281-5.
120. Gerebtzoff G, Seelig A. In silico prediction of blood-brain barrier permeation using the calculated molecular cross-sectional area as main parameter. J Chem Inf Model (2006) 46:2638-50. doi:10.1021/ci0600814.
121. Omote H, al-Shawi MK. Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys J (2006) 90:4046-59. doi:10.1529/biophysj.105.077743.
122. Clay AT, Sharom FJ. Lipid bilayer properties control membrane partitioning, binding, and transport of P-glycoprotein substrates. Biochemistry (2013) 52:343-54. doi:10.1021/bi301532c.
123. Eckford PD, Sharom FJ. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry (2008) 47:13686-98. doi:10.1021/bi801409r.
124. Romsicki Y, Sharom FJ. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry (1999) 38:6887-96. doi:10.1021/bi990064q.
125. Seelig A, Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci (2000) 12:31-40. doi:10.1016/S0928-0987(00)00177-9.
126. Gatlik-Landwojtowicz E, Aanismaa P, Seelig A. Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry (2006) 45:3020-32. doi:10.1021/bi051380+.
127. Aanismaa P, Seelig A. P-Glycoprotein kinetics measured in plasma membrane vesicles and living cells. Biochemistry (2007) 46:3394-404. doi:10.1021/bi0619526.
128. Heimburg T. Mechanical aspects of membrane thermodynamics. Estimation of the mechanical properties of lipid membranes close to the chain melting transition from calorimetry. Biochim Biophys Acta (1998) 1415:147-62. doi:10.1016/S0005-2736(98)00189-8.
129. Shimabuku AM, Nishimoto T, Ueda K, Komano T. P-glycoprotein. ATP hydrolysis by the N-terminal nucleotide-binding domain. J Biol Chem (1992) 267:4308-11.
130. Lerner-Marmarosh N, Gimi K, Urbatsch IL, Gros P, Senior AE. Large scale purification of detergent-soluble P-glycoprotein from Pichia pastoris cells and characterization of nucleotide binding properties of wild-type, Walker A, and Walker B mutant proteins. J Biol Chem (1999) 274:34711-8. doi:10.1074/jbc.274.49.34711.
131. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A (1992) 89:8472-6. doi:10.1073/pnas.89.18.8472.
132. Romsicki Y, Sharom FJ. The ATPase and ATP-binding functions of P-glycoprotein-modulation by interaction with defined phospholipids. Eur J Biochem (1998) 256:170-8. doi:10.1046/j.1432-1327.1998.2560170.x.
133. Aanismaa P, Gatlik-Landwojtowicz E, Seelig A. P-glycoprotein senses its substrates and the lateral membrane packing density: consequences for the catalytic cycle. Biochemistry (2008) 47:10197-207. doi:10.1021/bi800209h.
134. Liu R, Sharom FJ. Proximity of the nucleotide binding domains of the P-glycoprotein multidrug transporter to the membrane surface: a resonance energy transfer study. Biochemistry (1998) 37:6503-12. doi:10.1021/bi973031o.
135. Sharma S, Rose DR. Cloning, overexpression, purification, and characterization of the carboxyl-terminal nucleotide binding domain of P-glycoprotein. J Biol Chem (1995) 270:14085-93. doi:10.1074/jbc.270.23.14085.
136. Loo TW, Clarke DM. Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities. J Biol Chem (1995) 270:21449-52. doi:10.1074/jbc.270.37.21449.
137. Kimura Y, Kioka N, Kato H, Matsuo M, Ueda K. Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J (2007) 401:597-605. doi:10.1042/BJ20060632.
138. Weiss HM, Grisshammer R. Purification and characterization of the human adenosine A(2a) receptor functionally expressed in Escherichia coli. Eur J Biochem (2002) 269:82-92. doi:10.1046/j.0014-2956.2002.02618.x.
139. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol (2000) 58:624-32. doi:10.1124/mol.58.3.624.
140. Sharom FJ, Liu R, Qu Q, Romsicki Y. Exploring the structure and function of the P-glycoprotein multidrug transporter using fluorescence spectroscopic tools. Semin Cell Dev Biol (2001) 12:257-65. doi:10.1006/scdb.2000.0251.
141. Sharom FJ. Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem Cell Biol (2006) 84:979-92. doi:10.1139/o06-199.
142. Meier M, Blatter XL, Seelig A, Seelig J. Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity. Biophys J (2006) 91:2943-55. doi:10.1529/biophysj.106.089581.
143. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, et al. Reversal of multidrug resistance by surfactants. Br J Cancer (1992) 66:62-8. doi:10.1038/bjc.1992.217.
144. Regev R, Assaraf YG, Eytan GD. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem (1999) 259:18-24. doi:10.1046/j.1432-1327.1999.00037.x.
145. Coon JS, Knudson W, Clodfelter K, Lu B, Weinstein RS. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res (1991) 51:897-902.
146. Regev R, Katzir H, Yeheskely-Hayon D, Eytan GD. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. FEBS J (2007) 274:6204-14. doi:10.1111/j.1742-4658.2007.06140.x.
147. Dudeja PK, Anderson KM, Harris JS, Buckingham L, Coon JS. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch Biochem Biophys (1995) 319:309-15.
148. Lu P, Liu R, Sharom FJ. Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state. Eur J Biochem (2001) 268:1687-97. doi:10.1046/j.1432-1327.2001.02041.x.
149. Rogers JA, Davis SS. Functional group contributions to the partitioning of phenols between liposomes and water. Biochim Biophys Acta (1980) 598:392-404. doi:10.1016/0005-2736(80)90017-6.
150. Le Goff W, Settle M, Greene DJ, Morton RE, Smith JD. Reevaluation of the role of the multidrug-resistant P-glycoprotein in cellular cholesterol homeostasis. J Lipid Res (2006) 47:51-8. doi:10.1194/jlr.M500255-JLR200.
151. Bottova I, Hehl AB, Stefanic S, Fabrias G, Casas J, Schraner E, et al. Host cell P-glycoprotein is essential for cholesterol uptake and replication of Toxoplasma gondii. J Biol Chem (2009) 284:17438-48. doi:10.1074/jbc.M809420200.
152. Garrigues A, Escargueil AE, Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci U S A (2002) 99:10347-52. doi:10.1073/pnas.162366399.
153. Gayet L, Dayan G, Barakat S, Labialle S, Michaud M, Cogne S, et al. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. Biochemistry (2005) 44:4499-509. doi:10.1021/bi048669w.
154. Mayer dos Santos S, Weber CC, Franke C, Muller WE, Eckert GP. Cholesterol: coupling between membrane microenvironment and ABC transporter activity. Biochem Biophys Res Commun (2007) 354:216-21. doi:10.1016/j.bbrc.2006.12.202.
155. Arima H, Yunomae K, Morikawa T, Hirayama F, Uekama K. Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-β-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. Pharm Res (2004) 21:625-34. doi:10.1023/B:PHAM.0000022409.27896.d4.
156. Bucher K, Belli S, Wunderli-Allenspach H, Kramer SD. P-glycoprotein in proteoliposomes with low residual detergent: the effects of cholesterol. Pharm Res (2007) 24:1993-2004. doi:10.1007/s11095-007-9326-0.
157. Belli S, Elsener PM, Wunderli-Allenspach H, Kramer SD. Cholesterol-mediated activation of P-glycoprotein: distinct effects on basal and drug-induced ATPase activities. J Pharm Sci (2009) 98:1905-18. doi:10.1002/jps.21558.
158. Saeki T, Shimabuku AM, Azuma Y, Shibano Y, Komano T, Ueda K. Expression of human P-glycoprotein in yeast cells-effects of membrane component sterols on the activity of P-glycoprotein. Agric Biol Chem (1991) 55:1859-65. doi:10.1271/bbb1961.55.1859.
159. Saeki T, Shimabuku AM, Ueda K, Komano T. Specific drug binding by purified lipid-reconstituted P-glycoprotein: dependence on the lipid composition. Biochim Biophys Acta (1992) 1107:105-10. doi:10.1016/0005-2736(92)90334-I.
160. Wang EJ, Casciano CN, Clement RP, Johnson WW. Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Biochem Biophys Res Commun (2000) 276:909-16. doi:10.1006/bbrc.2000.3554.
161. Kimura Y, Morita SY, Matsuo M, Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci (2007) 98:1303-10. doi:10.1111/j.1349-7006.2007.00538.x.
162. Hamilton JA. Fast flip-flop of cholesterol and fatty acids in membranes: implications for membrane transport proteins. Curr Opin Lipidol (2003) 14:263-71. doi:10.1097/00041433-200306000-00006.
163. Leventis R, Silvius JR. Use of cyclodextrins to monitor transbilayer movement and differential lipid affinities of cholesterol. Biophys J (2001) 81:2257-67. doi:10.1016/S0006-3495(01)75873-0.
164. Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol (1998) 14:111-36. doi:10.1146/annurev.cellbio.14.1.111.
165. Orlowski S, Martin S, Escargueil A. P-glycoprotein and 'lipid rafts': some ambiguous mutual relationships (floating on them, building them or meeting them by chance?). Cell Mol Life Sci (2006) 63:1038-59. doi:10.1007/s00018-005-5554-9.
166. Radeva G, Perabo J, Sharom FJ. P-Glycoprotein is localized in intermediate-density membrane microdomains distinct from classical lipid rafts and caveolar domains. FEBS J (2005) 272:4924-37. doi:10.1111/j.1742-4658.2005.04905.x.
167. Reungpatthanaphong P, Marbeuf-Gueye C, Le Moyec L, Salerno M, Garnier-Suillerot A. Decrease of P-glycoprotein activity in K562/ADR cells by MβCD and filipin and lack of effect induced by cholesterol oxidase indicate that this transporter is not located in rafts. J Bioenerg Biomembr (2004) 36:533-43.
168. Kamau SW, Kramer SD, Gunthert M, Wunderli-Allenspach H. Effect of the modulation of the membrane lipid composition on the localization and function of P-glycoprotein in MDR1-MDCK cells. In vitro Cell Dev Biol Anim (2005) 41:207-16. doi:10.1290/0502016.1.
169. Anderson TG, Tan A, Ganz P, Seelig J. Calorimetric measurement of phospholipid interaction with methyl-β-cyclodextrin. Biochemistry (2004) 43:2251-61. doi:10.1021/bi0358869.
170. Klappe K, Hummel I, Hoekstra D, Kok JW. Lipid dependence of ABC transporter localization and function. Chem Phys Lipids (2009) 161:57-64. doi:10.1016/j.chemphyslip.2009.07.004.
171. Hinrichs JW, Klappe K, Van Riezen M, Kok JW. Drug resistance-associated changes in sphingolipids and ABC transporters occur in different regions of membrane domains. J Lipid Res (2005) 46:2367-76. doi:10.1194/jlr.M500070-JLR200.
172. Modok S, Heyward C, Callaghan R. P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterol-rich environment. J Lipid Res (2004) 45:1910-8. doi:10.1194/jlr.M400220-JLR200.
173. Kramer SD, Lombardi D, Primorac A, Thomae AV, Wunderli-Allenspach H. Lipid-bilayer permeation of drug-like compounds. Chem Biodivers (2009) 6:1900-16. doi:10.1002/cbdv.200900122.
174. Regev R, Eytan GD. Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochem Pharmacol (1997) 54:1151-8. doi:10.1016/S0006-2952(97)00326-2.
175. Sharom FJ, Lu P, Liu R, Yu X. Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation. Biochem J (1998) 333:621-30.
176. Nervi P, Li-Blatter X, Aanismaa P, Seelig A. P-glycoprotein substrate transport assessed by comparing cellular and vesicular ATPase activity. Biochim Biophys Acta (2010) 1798:515-25. doi:10.1016/j.bbamem.2009.11.022.
177. Eytan GD, Kuchel PW. Mechanism of action of P-glycoprotein in relation to passive membrane permeation. Int Rev Cytol (1999) 190:175-250. doi:10.1016/S0074-7696(08)62148-8.
178. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev (2002) 54:759-79. doi:10.1016/S0169-409X(02)00047-9.
179. Rege BD, Kao JP, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci (2002) 16:237-46. doi:10.1016/S0928-0987(02)00055-6.
180. Krylova OO, Melik-Nubarov NS, Badun GA, Ksenofontov AL, Menger FM, Yaroslavov AA. Pluronic L61 accelerates flip-flop and transbilayer doxorubicin permeation. Chemistry (2003) 9:3930-6. doi:10.1002/chem.200204621.